Prognostic Evaluation of Nodal Diffuse Large B Cell Lymphoma by Immunohistochemical Profiles with Emphasis on CD138 Expression as a Poor Prognostic Factor

Oh, Yu Whan; Park, Chan-Kum

doi:10.3346/jkms.2006.21.397

Cited by 11 publications

(36 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The majority of the seventeen studies reported using the same 56C6 antibody employed in our study (e.g. Linderoth et al, 2003;Chang et al, 2004;Hans et al, 2004;Oh and Park, 2006). Ohshima et al (2001) and Hoffman et al (2005) give Novocastra as their CD10 antibody source, while Muris et al (2006) give Monosan as their CD10 antibody sources, however both companies has more than one CD10 clone available (including 56C6) and the three studies do not specify which of the clones were used.…”

Section: Discussionmentioning

confidence: 91%

“…Tzankov et al, 2003;Chang et al, 2004;Hans et al, 2004;Hoffmann et al, 2005), seven studies did not report any significant difference (e.g. Braaten et al, 2003;Fabiani et al, 2004;Oh and Park, 2006;Liu et al, 2008), and two studies reported a statistically significant reduction of OS in association with positive BCL6 expression in DLBCL patients (Uherova et al, 2001;Xu et al, 2001).…”

Section: Discussionmentioning

confidence: 99%

“…Several studies reported no prognostic value of this marker (Fabiani et al, 2004;Hans et al, 2004;Oh and Park, 2006). while others reported that the positive expression of CD10 was associated with better OS (Oshima et al, 2001;Hans et al, 2004;Sjo et al, 2007), and poor OS (Uherova et al, 2001;Xu et al, 2001).…”

Section: Introductionmentioning

confidence: 99%

“…Two studies proposed the positive expression of CD138 as a marker of poor prognosis in DLBCL patients (Hoffmann et al, 2005;Oh and Park, 2006).…”

Section: Introductionmentioning

confidence: 99%

“…Different studies show conflicting results regarding the prognostic value of MUM-1, with some reporting poor prognostic value (Braaten et al, 2003;Oh and Park, 2006;Sjo et al, 2007) while others failing to find any significant prognostic value (Chang et al, 2004;Hans et al, 2004;Muris et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Evaluation of BCL-6, CD10, CD138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis

Bodoor

Matalka²,

Hayajneh³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The diffuse large B-cell lymphoma (DLBCL) encompasses two major groups of tumors with uneven survival outcomes -germinal center B-cell (GCB) and non-germinal center B-cell (non-GCB). In the present study, we investigated the expression of GCB markers (BCL-6 and CD10) and non-GCB markers (CD138 and MUM-1) in an effort to evaluate their prognostic value. Paraffin-embedded tumor biopsies of 46 Jordanian DLBCL patients were analyzed, retrospectively, by immunohistochemistry to investigate the expression of BCL-6, CD10, CD138 and MUM-1. In addition, survival curves were calculated with reference to marker expression, age, sex and nodal involvement. Positive expression of BCL-6, CD10, CD138 and MUM-1 was shown in 78%, 61%, 39% and 91% of the cases, respectively, that of BCL-6 being associated with better overall survival (p = 0.02), whereas positive CD138 was linked with poor overall survival (p = 0.01). The expression of CD10 and MUM-1 had no impact on the overall survival. Among the clinical characteristics studied, diagnosis at an early age, nodal involvement and maleness were associated with a higher overall survival for DLBCL patients. Our results underline the importance of BCL-6 as a marker of better prognosis and CD138 as a marker of poor prognosis for DLBCL patients.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Two studies proposed the positive expression of CD138 as a marker of poor prognosis in DLBCL patients (Hoffmann et al, 2005;Oh and Park, 2006).…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Evaluation of BCL-6, CD10, CD138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis

Bodoor

Matalka²,

Hayajneh³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

Antithetic roles of proteoglycans in cancer

Garusi

Rossi

Perris

2011

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

Proteoglycans (PGs), a family of complex post-translationally sculptured macromolecules, are fundamental regulators of most normal and aberrant cellular functions. The unparalleled structural-functional diversity of PGs endows them with the ability to serve as critical mediators of the tumor cells' interaction with the host microenvironment, while directly contributing to the organization and dynamic remodeling of this milieu. Despite their indisputable importance during embryonic development and in the adult organism, and their frequent dysregulation in tumor lesions, their precise involvement in tumorigenesis awaits a more decisive demonstration. Particularly challenging is to ascertain to what extent selected PGs may catalyze tumor progression and to what extent they may inhibit it, implying antithetic functions of individual PGs. Integrated efforts are needed to consolidate the routine use of PGs in the clinical monitoring of cancer patients and to broaden the exploitation of these macromolecules as therapeutic targets. Several PGs have the required attributes to be contemplated as effective antigens for immunotherapeutic approaches, while the tangible results obtained in recent clinical trials targeting the NG2/CSPG4 transmembrane PG urge further development of PG-based cancer treatment modalities.

show abstract

Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study

Chen

et al. 2010

Med Oncol

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) has been classified into different prognostic subgroups using immunohistochemistry in Western populations. However, the applicability in Chinese patients of these subgroups was unclear. We collected 116 specimens and performed immunohistochemical staining for CD10, BCL-6, MUM1, CD138, and CD5, and the results were classified into subgroups according to 3 different algorithms. We then analyzed the subgroups' correlation to patient survival. Expression of CD10 and BCL-6 predicted favorable 5-year OS (70 and 62.5%, respectively) and PFS (64.3 and 61.5%, respectively) rates. In contrast, the expression of MUM1 predicted unfavorable 5-year OS (23.1%) and PFS (17.9%) rates and was also independent of other markers. All algorithms led to useful subclassifications. Using Hans' algorithm based on CD10, BCL-6, and MUM1, the non-germinal center (GC) subgroup (66.4%) had worse 5-year OS (29.8%) and PFS (26.7%) rates than did the GC subgroup. Likewise, using Muris' algorithm based on CD10 and MUM1, fewer non-GC cases (27%) showed poorer OS (20.3%) and PFS (16.2%) rates than did GC cases, an effect that was independent of both the International Prognostic Index, a clinical indicator, and treatment. It identified a subgroup with a high-risk of death and seemed to be applicable in our series. In conclusion, these algorithms can be used effectively in Chinese patients with DLBCL.

show abstract

Prognostic Evaluation of Nodal Diffuse Large B Cell Lymphoma by Immunohistochemical Profiles with Emphasis on CD138 Expression as a Poor Prognostic Factor

Cited by 11 publications

References 25 publications

Evaluation of BCL-6, CD10, CD138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis

Evaluation of BCL-6, CD10, CD138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis

Antithetic roles of proteoglycans in cancer

Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study

Contact Info

Product

Resources

About